The global binge eating disorder market size was valued at USD 0.76 billion in 2023. The major drivers of the market include the growing awareness, surge in healthcare expenditure, access to advanced and novel therapeutics, increasing incidence of obesity, and rise in social media influence. The market is anticipated to grow at a CAGR of 6.1% during the forecast period 2024-2032 to reach a value of USD 1.28 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Binge eating disorder (BED) is a very common eating disorder in the United States. It has been suggested that binge eating disorder affects approximately 2.8 million people in the USA. People with the condition consume excessive amounts of food in a single sitting. During periods of binging, these individuals experience a sense of loss of control over their eating. Such binging episodes are often followed by feelings of guilt or shame. Binge eating has been associated with being overweight and obese. However, it is possible to be obese and not have binge eating disorder. Individuals with eating disorders often suffer in silence. It is thus difficult to identify the number of people affected by these disorders. It has been reported that just three percent of adults in USA who fulfilled the criteria for binge eating disorder received a diagnosis from their doctor. It is thus suggested that several individuals with the disorder do not receive medical treatment.
Binge eating disorder may be seen in across all age groups, races, and income levels, however, it seems most prevalent among women. Among men, it is the most common eating disorder. Symptoms of binge eating disorder include:
In addition, people with binge eating disorder must exhibit at least three of the following symptoms:
Individuals with the disorder do not try to compensate for their binges with unhealthy actions, such as dietary restriction or fasting, excessive exercising, and purging via self-induced vomiting or laxative abuse.
Binge eating disorder may result in several health risks usually associated with obesity, including diabetes, high cholesterol, high blood-pressure, heart, disease, osteoarthritis, sleep apnoea, etc. Individuals with binge eating disorder may also experience anxiety, depression, low self-esteem, and other conditions that significantly affect quality of life.
Treatment for binge eating disorder is available and recovery possible. Growing awareness around the disorder and an increased number of doctors trained in the treatment of binge eating disorder has made it easier for people to receive treatment. These factors are expected to drive global binge eating disorder market growth. Treatments may usually involve a combination of psychotherapy, psychiatric intervention, and proper nutrition.
Treatment goals include reducing binge eating and supporting the person to eat regular meals. It is also important to address other associated emotional factors such as anxiety, depression, and self-esteem.
Leading companies are engaged in developing treatments for patients with binge eating disorder. Such developments are expected to boost the global binge eating disorder market.
For example, in 2023, Tonix Pharmaceuticals Holding Corp. a clinical-stage biopharmaceutical company, announced an agreement with Massachusetts General Hospital, to evaluate TNX-1900 in an investigator initiated Phase 2 clinical trial as a probable treatment for individuals with binge eating disorder. The Phase 2 clinical trial was expected to start in the second half of 2023. Oxytocin, a well-known natural hormone used therapeutically in particular other indications including as an i.v. medication for the induction of labour in pregnancy with a medical indication; the proprietary intranasal dosage form was expected to enhance its properties for use in the underserved population of patients suffering from binge eating disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By treatment, the market is segmented into:
By distribution channel, the market is classified into:
By region, the market is divided into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global binge eating disorder market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Treatment||
|Breakup by Services||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Binge Eating Disorder Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Binge Eating Disorder Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Binge Eating Disorder Epidemiology (2016-2031)
5.3 Europe Binge Eating Disorder Epidemiology (2016-2031)
5.4 Asia-Pacific Binge Eating Disorder Epidemiology (2016-2031)
5.5 Latin America Binge Eating Disorder Epidemiology (2016-2031)
5.6 Middle East & Africa Binge Eating Disorder Epidemiology (2016-2031)
6 Global Binge Eating Disorder Market Overview
6.1 Global Binge Eating Disorder Market Historical Value (2017-2023)
6.2 Global Binge Eating Disorder Market Forecast Value (2024-2032)
7 Global Binge Eating Disorder Market Landscape
7.1 Global Binge Eating Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Binge Eating Disorder Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channel
8 Binge Eating Disorder Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Binge Eating Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Binge Eating Disorder Market Segmentation
11.1 Global Binge Eating Disorder Market by Treatment
11.1.1 Market Overview
220.127.116.11 Anti-obesity Medication
11.2 Global Binge Eating Disorder Market by Services
11.3 Global Binge Eating Disorder Market by Route of Administration
11.3.1 Market Overview
11.4 Global Binge Eating Disorder Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.5 Global Binge Eating Disorder Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Binge Eating Disorder Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Binge Eating Disorder Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Binge Eating Disorder Market
14.1 Market Share by Country
15 Latin America Binge Eating Disorder Market
15.1 Market Share by Country
16 Middle East and Africa Binge Eating Disorder Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
23 Supplier Landscape
23.1 Tonix Pharmaceuticals Holding Corp.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Takeda Pharmaceutical Company Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Chronos Therapeutics Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Pyramid Healthcare Inc.
23.4.1 Financial Analysis
23.4.2 Financial Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 VIVUS LLC.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Sunovion Pharmaceuticals Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 H. Lundbeck A/S
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Orexigen Therapeutics, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Novo Nordisk A/S
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Eli Lily and Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Jazz Pharmaceuticals Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
24 Global Binge Eating Disorder Market - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The global binge eating disorder market reached a value of USD 0.76 billion in 2023.
The market is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to reach a value of USD 1.28 billion by 2032.
The major drivers of the market include the growing awareness, surge in healthcare expenditure, access to advanced and novel therapeutics, increasing incidence of obesity, and rise in social media influence.
Rise in prevalence of eating disorder and increasing number of doctors treating binge eating disorder are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The various treatments for binge eating disorder in the market are medication and services. Medication is further broken down into antidepressant, anticonvulsant, and anti-obesity medication, among others, while services are divided into inpatient and outpatient.
The several distribution channels of the market are retail pharmacy, hospital pharmacy, and online pharmacy.
The major players in the industry are Tonix Pharmaceuticals Holding Corp., Takeda Pharmaceutical Company Limited, Chronos Therapeutics Limited, Pyramid Healthcare Inc., and VIVUS LLC., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.